Effect of enalapril on diabetic neuropathy

Phase 2

Conditions: E10, E11
Diabetic Neuropathy.
Insulin-dependent diabetes mellitus, Non-Insulin-dependent diabetes mellitus

Registration Number: IRCT2014061118063N1

Lead Sponsor: Vice-chancellor for research - Birjand University of Medical Sciences

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Complete

Sex: All

Target Recruitment: 30

Inclusion Criteria

Diabetes type 2 diabetes based on the criteria of american diabetes association (blood sugar after 10 to 12 hours of fasting be more than 126 mg/dl or random BS equal or more than 200 mg/dl) at least for 3 years; Having mild to moderate neuropathy (grade 3 to 5 based on Michigan scoring system); Age between 30 to 80
Exclusion criteria: history of enalapril consumption during a recent year; Consumers of alcohol; Kidney disease patients; Liver disease patients (moderate to severe); The existence of a wound in the foot; amputation of the lower extremities; Developing gestational diabetes in women; history of hereditary neuropathy or background diseases causing neuropathy; Taking TCA antidepressants drugs; A lack of vitamin B12 (not less than 160mg / dl); A history of renal arteries stenosis; Having one kidney or micro-albuminuria; Sensitivity to ACD inhibitors; Long-term use of non-steroidal inflammatory drugs such as aspirin during the 4 weeks prior to the disease

Exclusion Criteria

Not provided

Study & Design

Study Type: interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Velocity of nerve conduction. Timepoint: before intervention - after intervention. Method of measurement: EMG-NCV.;Amplitude of nerve conduction. Timepoint: before intervention - after intervention. Method of measurement: EMG-NCV.;Latency (s) of nerve conduction. Timepoint: before intervention - after intervention. Method of measurement: EMG-NCV.;Latency (m) of nerve conduction. Timepoint: before intervention - after intervention. Method of measurement: EMG-NCV.

Secondary Outcome Measures